Clinical Significance of Background Parenchymal Enhancement in Breast Cancer Risk Stratification

By sjmartinez • September 20, 2023

Murakami W, Mortazavi S, Yu T, Kathuria-Prakash N, Yan R, Fischer C, McCann KE, Lee-Felker S, Sung. Clinical Significance of Background Parenchymal Enhancement in Breast Cancer Risk Stratification. J Magn Reson Imaging. 2023 Sep 19. doi: 10.1002/jmri.29015. Epub ahead of print. PMID: 37724902.

Tags: background parenchymal enhancement (BPE), BRCA, breast MRI, Fellow, Hematology/Oncology, high-risk screening, lifetime risk, Publications

Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm

De Botton S, Récher C, Cortes J, Curti A, Fenaux P, Peterlin P, Pigneux A, Yee K, Wei A, Mims A, Schiller G, Chao MM,[...]

Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now

Shore N, Nielsen SM, Esplin ED, Antonarakis ES, Barata PC, Beer TM, Beltran H, Bryce A, Cookson MS, Crawford ED, Dorff TB, George DJ, Heath[...]

Retrospective Study of CD20 Expression Loss in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Marshalek JP, Qing X, Dragan M, Tomassetti S. Retrospective Study of CD20 Expression Loss in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. J Hematol. 2024 Dec;13(6):268-277.[...]